Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/30532
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorBernal-Soriano, Mari Carmen-
dc.contributor.authorParker, Lucy Anne-
dc.contributor.authorLopez-Garrigos, Maite-
dc.contributor.authorHernández-Aguado, Ildefonso-
dc.contributor.authorCaballero-Romeu, Juan-Pablo-
dc.contributor.authorGómez-Pérez, Luis-
dc.contributor.authorALFAYATE-
dc.contributor.authorPastor-Valero, Maria-
dc.contributor.authorGarcía, Nuria-
dc.contributor.authorLumbreras, Blanca-
dc.contributor.otherDepartamentos de la UMH::Salud Pública, Historia de la Ciencia y Ginecologíaes_ES
dc.date.accessioned2024-01-17T17:42:37Z-
dc.date.available2024-01-17T17:42:37Z-
dc.date.created2019-10-
dc.identifier.citationMedicine 2019 Oct; 98(40)es_ES
dc.identifier.issn1536-5964-
dc.identifier.issn0025-7974-
dc.identifier.urihttps://hdl.handle.net/11000/30532-
dc.description.abstractProstate-specific antigen (PSA) is the main tool for early detection, risk stratification and monitoring of prostate cancer (PCa). However, there are controversies about the use of PSA as a population screening test because of the high potential for overdiagnosis and overtreatment associated. The net benefit of screening is unclear and according to the available recommendations, it should be offered to well-informed men with an adequate health status and a life-expectancy of at least 10 years or to men at elevated risk of having PCa. In addition, the factors that influence test results are unclear, as is impact of false positive or negative results on patient health. Our objective is to assess the clinical and analytical factors associated with the presence of false positive and false negative results and the diagnostic/therapeutic process followed by these patients. Methods and analysis: A prospective observational cohort study will be carried out. We will include a cohort of patients with a positive PSA result (1.081 patients) and a sample of patients with negative results (572 patients); both will be followed for 2 years by reviewing medical records to assess the variables associated with these results, as well as characteristics of patient management after a positive PSA value. We will include those patients with a PSA determination from 2 hospitals in the Valencian Community. Patients who have been previously diagnosed with prostate cancer or who are being followed for previous high PSA values will be excluded. Discussion: The study will estimate the frequency of false positive and false negative PSA results in routine clinical practice, and allow us to quantify the potential harm causedes_ES
dc.formatapplication/pdfes_ES
dc.format.extent7es_ES
dc.language.isoenges_ES
dc.publisherWolters Kluwer Healthes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectfalse negative reactionses_ES
dc.subjectfalse positive reactionses_ES
dc.subjectprostate diseasees_ES
dc.subjectprostate-specific antigenes_ES
dc.subjectquality in health carees_ES
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicinaes_ES
dc.titleFactors associated with false negative and false positive results of prostate-specific antigen (PSA) and the impact on patient healthes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1097/MD.0000000000017451es_ES
Aparece en las colecciones:
Artículos Salud Pública, Historia de la Ciencia y Ginecología


Vista previa

Ver/Abrir:
 13-Medicine-2019.pdf

297,94 kB
Adobe PDF
Compartir:


Creative Commons La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.